[go: up one dir, main page]

EA200200295A1 - Композиции с микрочастицами бупренорфина для инъекций и их применение - Google Patents

Композиции с микрочастицами бупренорфина для инъекций и их применение

Info

Publication number
EA200200295A1
EA200200295A1 EA200200295A EA200200295A EA200200295A1 EA 200200295 A1 EA200200295 A1 EA 200200295A1 EA 200200295 A EA200200295 A EA 200200295A EA 200200295 A EA200200295 A EA 200200295A EA 200200295 A1 EA200200295 A1 EA 200200295A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
buprenorphine
partial
opioid antagonist
opioid agonist
Prior art date
Application number
EA200200295A
Other languages
English (en)
Other versions
EA009080B1 (ru
Inventor
Томас Р. Тайс
Джей К. Стаас
Тереза М. Феррелл
Питер Марклэнд
Original Assignee
Саутерн Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саутерн Рисерч Инститьют filed Critical Саутерн Рисерч Инститьют
Publication of EA200200295A1 publication Critical patent/EA200200295A1/ru
Publication of EA009080B1 publication Critical patent/EA009080B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложена пригодная для инъекций композиция замедленного высвобождения частичного агониста опиоида или антагониста опиоида, включающая частичный агонист опиоида или антагонист опиоида в поли(D,L-лактидном) носителе с малым количеством этилацетата. После внутримышечного введения композиции частичный агонист опиоида или антагонист опиоида высвобождается регулируемым образом в течение протяженного периода времени. Композиция находит применение при лечении субъектов, приверженных к героину и алкоголю, для уменьшения потребления вызывающих зависимость химических веществ. Особый интерес представляют лекарства бупренорфин, метадон и налтрексон.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200295A 1999-08-27 2000-08-25 Композиции с микрочастицами бупренорфина для инъекций и их применение EA009080B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15111299P 1999-08-27 1999-08-27
PCT/US2000/023390 WO2001015699A1 (en) 1999-08-27 2000-08-25 Injectable buprenorphine microparticle compositions and their use

Publications (2)

Publication Number Publication Date
EA200200295A1 true EA200200295A1 (ru) 2002-08-29
EA009080B1 EA009080B1 (ru) 2007-10-26

Family

ID=22537367

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200295A EA009080B1 (ru) 1999-08-27 2000-08-25 Композиции с микрочастицами бупренорфина для инъекций и их применение

Country Status (24)

Country Link
US (2) US6495155B1 (ru)
EP (1) EP1212061B1 (ru)
JP (1) JP4913298B2 (ru)
KR (1) KR100730440B1 (ru)
CN (2) CN1248689C (ru)
AT (1) ATE280579T1 (ru)
AU (1) AU765496C (ru)
BR (1) BR0013650A (ru)
CA (1) CA2382577C (ru)
CY (1) CY1106043T1 (ru)
CZ (1) CZ2002728A3 (ru)
DE (1) DE60015370T2 (ru)
EA (1) EA009080B1 (ru)
ES (1) ES2230154T3 (ru)
HK (1) HK1046858B (ru)
HU (1) HUP0203613A3 (ru)
IL (2) IL148343A0 (ru)
MX (1) MXPA02002105A (ru)
NO (2) NO322650B1 (ru)
NZ (1) NZ517997A (ru)
PL (1) PL198334B1 (ru)
PT (1) PT1212061E (ru)
RO (1) RO121631B1 (ru)
WO (1) WO2001015699A1 (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1212061E (pt) * 1999-08-27 2005-01-31 Southern Res Inst Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
EP1411861B1 (en) * 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
US20030130297A1 (en) 2001-07-06 2003-07-10 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE60223254T2 (de) 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
EP1429730A4 (en) * 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
SI1610791T1 (sl) 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
JP5208504B2 (ja) 2004-08-04 2013-06-12 クリヌベール、ファーマスーティカルズ、リミテッド 対象者でメラニン形成を誘導するための方法
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
DK2197429T3 (en) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Particulate compositions for delivery of poorly soluble drugs
EP2222281B1 (en) * 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
JP5453434B2 (ja) 2008-09-24 2014-03-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対する耐性を有するオピオイドではないｐＨ依存の制御放出の医薬組成物
CN102164588B (zh) * 2008-09-24 2015-07-08 赢创罗姆有限公司 耐受乙醇影响的pH依赖性受控释放的药物组合物
US20100268191A1 (en) * 2009-04-21 2010-10-21 Medtronic Vascular, Inc. Drug Delivery Catheter using Frangible Microcapsules and Delivery Method
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
DE112013002074T5 (de) 2012-04-17 2015-01-29 Purdue Pharma L.P. Systeme und Methoden zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion
CN102836131A (zh) * 2012-09-28 2012-12-26 山东大学 丁丙诺啡皮下注射用缓释微球制剂及其制备方法
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
JP2019510008A (ja) 2016-02-23 2019-04-11 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド 持続放出性ブプレノルフィンミクロスフェア（ｓｒｂｍ）及びその使用方法
HUE060906T2 (hu) 2016-09-13 2023-04-28 Alar Pharmaceuticals Inc Nyújtott felszabadulású buprenorfin-készítmények
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3089256C (en) 2018-05-11 2023-10-10 Alar Pharmaceuticals Inc. Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
EP4013390A1 (en) * 2019-08-12 2022-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pharmaceutical compositions comprising a combination of opioid antagonists
US20210059943A1 (en) * 2019-09-04 2021-03-04 Buffalo Pacific LLC Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5716631A (en) 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
PT1212061E (pt) * 1999-08-27 2005-01-31 Southern Res Inst Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes

Also Published As

Publication number Publication date
DE60015370D1 (de) 2004-12-02
EP1212061A1 (en) 2002-06-12
PL354977A1 (en) 2004-03-22
NO20020924L (no) 2002-04-03
NO322650B1 (no) 2006-11-13
EP1212061B1 (en) 2004-10-27
AU7075100A (en) 2001-03-26
US7473431B2 (en) 2009-01-06
HK1046858B (en) 2005-03-24
HUP0203613A3 (en) 2005-01-28
NO20063239L (no) 2002-04-03
BR0013650A (pt) 2002-05-07
CN1248689C (zh) 2006-04-05
ATE280579T1 (de) 2004-11-15
AU765496B2 (en) 2003-09-18
AU765496C (en) 2005-08-25
EA009080B1 (ru) 2007-10-26
MXPA02002105A (es) 2003-12-11
CN100387228C (zh) 2008-05-14
PT1212061E (pt) 2005-01-31
IL148343A0 (en) 2002-09-12
PL198334B1 (pl) 2008-06-30
CA2382577A1 (en) 2001-03-08
CY1106043T1 (el) 2011-04-06
KR100730440B1 (ko) 2007-06-19
JP4913298B2 (ja) 2012-04-11
DE60015370T2 (de) 2006-03-09
IL148343A (en) 2008-03-20
HK1046858A1 (en) 2003-01-30
HUP0203613A2 (hu) 2003-02-28
CN1382051A (zh) 2002-11-27
NZ517997A (en) 2002-11-26
RO121631B1 (ro) 2008-01-30
US20030152638A1 (en) 2003-08-14
CZ2002728A3 (cs) 2002-08-14
JP2003508439A (ja) 2003-03-04
NO20020924D0 (no) 2002-02-26
CA2382577C (en) 2008-01-22
CN1788721A (zh) 2006-06-21
US6495155B1 (en) 2002-12-17
KR20020053057A (ko) 2002-07-04
ES2230154T3 (es) 2005-05-01
WO2001015699A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
EA200200295A1 (ru) Композиции с микрочастицами бупренорфина для инъекций и их применение
EA200101062A1 (ru) Композиции микросфер налтрексона для инъекций и их применение для уменьшения потребления героина и алкоголя
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
KR910002444A (ko) 스피로사이클릭 피페리딘 유도체, 이의 제조방법, 이의 용도 및 이를 함유하는 약학 조성물
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
Endoh et al. Characterization of the antinociceptive effects of TRK-820 in the rat
Kamerling et al. Narcotic analgesics, their detection and pain measurement in the horse: a review
Bhargava The effects of thyrotropin-releasing hormone on the central nervous system responses to chronic morphine administration
Dykstra et al. Antagonism of morphine by long acting narcotic antagonists
ATE287265T1 (de) Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz
EP1555023A3 (en) Injectable buprenorphine microparticle compositions and their use
Lewis et al. 14-Amino-4, 5-epoxymorphinan derivatives and their pharmacological actions
PE20020041A1 (es) Combinacion farmaceutica que comprende un compuesto de efecto opioide y un compuesto peptidico
MXPA06002025A (es) Una composicion farmaceutica para la prevencion y tratamiento de adiccion de un mamifero.
DE60003158D1 (de) Benzimidazolverbindungen zur anwendung als therapeutisch wirksame substanzen, verfahren zur herstellung dieser verbindungen und pharmazeutische zusammensetzungen die diese enthalten
Murray et al. Neuroadaptation of rats to kappa agonists U-50,488 and tifluadom
Földes et al. Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by D-Met2, Pro5-enkephalinamide in man
Aceto et al. Dependence studies of new compounds in the rhesus monkey, rat and mouse (1993)
Konstantinopol'skiĭ et al. The withdrawal syndrome and lipid peroxidation during the chronic administration of narcotic analgesics to rats
Howes et al. Development of TR5379M (Xorphanol mesylate), an oral analgesic
Okuda et al. Prolonged antinociceptive effect after epidural injection of polyethylene glycol-morphine composites in rats
IT1260498B (it) Composizioni terapeutiche a rilascio ritardato atte ad inibire l'assunzione di oppiacei

Legal Events

Date Code Title Description
FA9A Withdrawal of a eurasian application
NF9A Restoration of lapsed right to a eurasian application

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU